Close Menu

NEW YORK – Diagnostics developer Quidel announced Monday that it has received Emergency Use Authorization from the US Food and Drug Administration for a readerless rapid antigen test to detect SARS-CoV-2 infection.

The test, called the QuickVue SARS Antigen test, is authorized for point-of-care use directly from patient anterior nares swab samples within the first five days of symptom onset, the firm said in a statement.

Quidel said it expects to ramp its manufacturing up to 600 million QuickVue SARS Antigen tests per year by the end of 2021.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.